Reta vs Semaglutide: Mechanism & Research Comparison
Last updated: 9 June 2026
An objective research comparison. The reta supplied by DXB Peptides is for in vitro laboratory research only — not for human consumption.
Reta and semaglutide are often compared because both belong to the family of nutrient-hormone-based metabolic compounds — but they represent two different generations. Semaglutide is an established, approved single-receptor agonist; reta is an investigational triple agonist still in clinical development. This page compares their mechanisms, the trial data published to date, and their development status, for research and informational context only.
At a glance
| Reta | Semaglutide | |
|---|---|---|
| Receptors targeted | Three: GLP-1, GIP, and glucagon | One: GLP-1 |
| Class | Triple agonist (investigational) | GLP-1 receptor agonist |
| Development stage | Phase 3 — investigational | Approved (Ozempic / Wegovy) |
| Reported trial weight reduction | ~24% at 48 weeks (Phase 2) | ~15% at 68 weeks (STEP) |
| Approved for human use? | No | Yes |
The mechanistic difference
The clearest way to understand the two is by counting receptors. Semaglutide activates a single pathway — the GLP-1 receptor — which reduces appetite and slows gastric emptying. Reta activates three pathways at once: GLP-1, GIP, and the glucagon receptor.
The glucagon receptor is the defining addition. Beyond the appetite-related effects shared with GLP-1 and GIP signalling, glucagon-receptor activation is involved in hepatic glucose regulation and energy expenditure. In research terms, this is what distinguishes a triple agonist from the single- and dual-agonist generations that preceded it.
What the trials reported
In its Phase 2 obesity trial, published in the New England Journal of Medicine in 2023, reta produced a mean weight reduction of roughly 24% at 48 weeks at the highest (12 mg) dose. Semaglutide, in the STEP program, produced reductions on the order of 15% at 68 weeks in adults without diabetes. More recent Phase 3 reporting for reta has indicated even larger reductions.
An important caveat: these figures come from different trials, with different populations and timeframes — they are not a head-to-head comparison. The numbers are informative about each compound individually, but the gap between them should not be read as a precise, validated difference. Only a direct comparative trial could establish that.
Development status and track record
This is where the two diverge most sharply. Semaglutide has been approved and marketed since 2017 (as Ozempic for type 2 diabetes and Wegovy for weight management), giving it years of real-world data and a large body of cardiovascular-outcome evidence. Reta, by contrast, remains investigational: it is in Phase 3 trials and is not approved for human use in any jurisdiction. It is not expected to be commercially available before 2027 at the earliest.
Both compounds share a broadly similar side-effect profile dominated by gastrointestinal symptoms such as nausea, reported in their respective trials — a class characteristic rather than a point of differentiation.
Learn more
For a fuller picture of reta’s mechanism and research record, see our reta research overview. DXB Peptides supplies research-grade reta for in vitro laboratory use — HPLC-tested to ≥99% purity with a batch-specific COA, cold-chain handled and delivered across the UAE.
Frequently asked questions
What is the main difference between reta and semaglutide? The number of receptors they engage. Semaglutide is a single-receptor (GLP-1) agonist; reta is a triple agonist targeting GLP-1, GIP, and glucagon receptors.
Does reta produce more weight reduction than semaglutide? In their separate trials, reta reported larger reductions (~24% vs ~15%). However, these were not head-to-head trials, so the comparison has real limitations.
Is reta approved? No. It is investigational and in Phase 3 trials. Semaglutide is approved and has been marketed since 2017.
Are they the same class of compound? They are related — both act on nutrient-hormone receptors including GLP-1 — but semaglutide is a GLP-1 agonist while reta is a triple agonist, a distinct and newer category.
Important note
This page is an objective comparison for research and informational purposes and is not medical advice. The reta supplied by DXB Peptides is a research compound for in vitro laboratory use only — it is not approved for human use and is not for human consumption or in vivo administration.
Explore the full catalogue: Research peptides UAE